EN DE
Watch Picard Medical, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Picard Medical, Inc (PMI) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Picard Medical, Inc stock $6.63, price $8.44, that is 21.4% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PM Picard Medical, Inc logo Thin data Nov 10, 2026

Picard Medical, Inc

PMI · US
Expensive, weak quality

Our calculation puts a fair price 21% below what the stock costs today.

Low debt
Revenue last quarter +39% vs. a year ago.
Quality 42/100
Expensive Growth (revenue 3y +6.3 %/yr in USD)
Mixed vs. peers (4/9)
Fair value $6.63 · Overvalued
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Picard Medical, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$660.00 $3.03 Fair Value $6.63 Aug 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

14‑month range $3.03 – $660.00 · fair‑value band $4.97 – $8.29 · the $8.44 price screens above the $6.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Picard Medical in your weekly email

Every Wednesday you see whether Picard Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.

Show moreShow less

The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the United States, Europe, and internationally.

The company was incorporated in 2021 and is headquartered in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc.

Stock analysis

Picard Medical, Inc (PMI) currently trades at $8.44, while our estimate is $6.63, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.97 (bear) to $8.29 (bull), the price of $8.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Picard Medical, Inc reported revenue of $4.9M in FY2025 versus $4.1M in FY2022, a compound +6.3%/yr. Reported net income was −$27.0M in FY2025.

Key figures

Market cap $15.7M Micro · P/S ratio 2.68 · EPS (TTM) $−6.93 · Return on assets (EBIT) −94.5% (4-year average) · Operating margin −157% · Revenue (TTM) $6.3M · Revenue growth (YoY) +38.6% · Free cash flow −$15.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and 179% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at −21%, PMI screens richer than that median.

Fair Value

Bear $4.97 Fair Value $6.63 Bull $8.29
Price $8.44 · Downside -21.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 32
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 39
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−269.1% (2022) → −259.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PMI screens overvalued: fair value 21% below the price. Compare with Abbott Laboratories, →

Compare Picard Medical, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −21.4% · Below median
Profitability
Return on assets −119.7% · Bottom 25%
Operating margin (12 months) −156.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 38.6% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 4.13× · Priciest 25%
P/S (12 months) 2.49× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 16
FUTURE (revenue growth)100 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥181.10 ¥202.57 +12% vs PMI
Stryker Corporation SYK $325.73 $358.46 +10% vs PMI
Boston Scientific Corporation BSX $44.02 $48.42 +10% vs PMI
DexCom, Inc DXCM $81.07 $89.18 +10% vs PMI
STERIS plc STE $256.94 $279.53 +9% vs PMI
GE HealthCare Technologies Inc GEHC $84.03 $69.92 −17% vs PMI
Edwards Lifesciences Corporation EW $104.71 $81.94 −22% vs PMI
Abbott Laboratories, ABT $110.51 $75.28 −32% vs PMI
Medtronic plc MDT $102.79 $65.61 −36% vs PMI
Koninklijke Philips N.V PHIA €27.30 €15.23 −44% vs PMI

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Picard Medical, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Picard Medical, Inc Fair Value". https://www.fairvalue-calculator.com/stock/PMI

Frequently asked questions

Is Picard Medical, Inc (PMI) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $6.63 versus a price of $8.44, about 21% lower (overvalued).
What is the fair value of PMI?
Our estimate for Picard Medical, Inc is $6.63 (as of Nov 10, 2026), built from audited fundamentals. The current price: $8.44.
What is the quality score of PMI?
Picard Medical, Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Picard Medical, Inc (PMI)?
Our calculated price target is the estimate of $6.63 (as of Nov 10, 2026). Cautious scenario $4.97, optimistic scenario $8.29. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Picard Medical, Inc stock forecast for 2026?
Our estimate puts fair value at $6.63, about 21% lower versus a price of $8.44 (overvalued). Cautious scenario $4.97, optimistic scenario $8.29. The calculation is refreshed regularly with new filings.
What is the revenue of Picard Medical, Inc (PMI)?
Picard Medical, Inc reported trailing-twelve-month revenue of about $6.3M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Picard Medical, Inc (PMI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Picard Medical, Inc it is $6.63 per share (as of Nov 10, 2026), against a price of $8.44.
Is Picard Medical, Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PMI trades above its calculated fair value: price $8.44, fair value $6.63, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PMI?
No. The price is what the market pays today ($8.44); the fair value is what the company's own numbers justify ($6.63). For Picard Medical, Inc the two are $1.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Picard Medical, Inc worth?
The market values Picard Medical, Inc at about $15.7M (market capitalisation, as of Nov 10, 2026). Per share that is $8.44; our models calculate a fair value of $6.63 per share.
What do the bullish and bearish scenarios say about PMI?
Our models span a range for Picard Medical, Inc: cautious scenario $4.97, base $6.63, optimistic $8.29 per share (as of Nov 10, 2026, price $8.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is PMI from its 52-week high?
Picard Medical, Inc trades at $8.44, about 95% below its 52-week high of $184.50 and 179% above the low of $3.03 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $6.63 is for.
Which stocks are comparable to Picard Medical, Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Picard Medical, Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $8.44, calculated fair value $6.63 (−21%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Picard Medical, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Picard Medical, Inc (PMI)?
The closing price on Nov 9, 2026 was $8.44. Our estimate is $6.63, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Picard Medical, Inc right now?
Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Picard Medical, Inc

How large is the market capitalisation of Picard Medical, Inc (PMI)?
The market capitalisation of Picard Medical, Inc is $15.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Picard Medical, Inc (PMI)?
The price-to-sales ratio of Picard Medical, Inc is 2.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Picard Medical, Inc (PMI)?
Earnings per share at Picard Medical, Inc are $−6.93. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Picard Medical, Inc (PMI)?
On an EBIT basis the return on assets of Picard Medical, Inc is −94.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Picard Medical, Inc (PMI)?
The operating margin of Picard Medical, Inc is −157% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Picard Medical, Inc (PMI)?
Revenue at Picard Medical, Inc is growing +38.6% versus a year earlier (3y avg +6.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Picard Medical, Inc (PMI) generate?
The free cash flow of Picard Medical, Inc is −$15.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Picard Medical, Inc (PMI) hold?
Picard Medical, Inc holds more cash than debt, $476K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Picard Medical, Inc in the live analysis

One click puts Picard Medical, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.